05 mg/dl, range 0 49 – 7 36 mg/dl) and two years after OLT (media

05 mg/dl, range 0.49 – 7.36 mg/dl) and two years after OLT (median 1.18, range 0.67 – 4.73 mg/dl). Acute renal failure affected 31.9% (n=51/160) within a median of 26 days (mean 92 days) after 〇LT. Hemodialysis was performed in 26.3% (n=40/152) and was started within a median interval of 5 days (mean 55 days) after 〇LT. Obesity (BMI>30 kg/m2), history of alcohol abuse, high creatinin levels and low HbA1c at baseline were linked

to acute renal failure. Low HbA1c as well as high creatinin levels at baseline were additionally linked to de novo hemodialysis. Post hoc analysis of HBa1c levels identified their negative correlation with serum bilirubin (p = 0.008) and a VX-809 in vivo positive correlation with serum albumin (P = 0.01 3). Conclusion: Our data confirmed the high prevalence

of acute renal failure after 〇LT. Besides pre-existing obesity, renal insufficiency and history of alcohol abuse, also low HbA1c (≤4.4%) levels were associated with both hepatic and renal impairment in patients receiving 〇LT. Reduced HbA1c levels might therefore be a risk factor for post 〇LT renal complications, as it may represent increased erythrocyte turnover and impaired gluconeogenesis in end stage liver disease. Disclosures: Arndt Weinmann – Speaking and Teaching: Bayer Healthcare Peter R. Galle – Advisory Committees or Review Panels: Bayer, BMS, Lilly, Daiichi, Jennerex; Consulting: Medimmune; Grant/Research Support: Roche, Lilly; Speaking and Teaching: Bayer, BMS The following people have nothing Tyrosine Kinase Inhibitor Library to disclose:

Steffen Gerbermann, Hanna E. Tönissen, Sandra Koch, Pomalidomide research buy Maria Hoppe-Lotichius, Tim Zimmermann, Jens Mittler, Hauke Lang, Gerd Otto, Martin F. Sprinzl Liver transplantation (LT) is a life-saving therapy in advanced cirrhosis, but its use is limited by the availability of suitable organs. While it is recognized that HCV-infected LT recipients suffer compromised outcomes overall, the contribution of donor factors to HCV recurrence and progression is not well-elucidated. We therefore undertook this study to assess the impact of the donor risk index (DRI) and other donor characteristics on fibrosis progression, graft and patient survival in a cohort of HCV-infected LT recipients. Methods: Adults who had undergone LT at our center between 1998 and 2012 for HCV were included in survival analysis. Those who had at least 2 post-LT protocol liver biopsy (LBx) specimens available were included in histological assessment. Patients were excluded for concomitant HIV/ HBV, post-LT follow-up < 4 months, prior LT, or undetectable HCV RNA post- LT. Institutional Review Board approval was obtained. Biopsy samples were reviewed by a single pathologist for steatosis, fibrosis stage and inflammatory grade (METAVIR). Data was abstracted and entered into a prospectively maintained web-based database (REDCap). Hazard ratio for bivariate analysis were computed using Cox proportional hazard regression analysis.

Comments are closed.